---

---

treatment   publishing date : 2021 - 05 - 03   

save search

---

Hawaii Water Service Completes Purchase of Kapalua Water Company and Kapalua Waste Treatment Company
Published: 2021-05-03 (Crawled : 00:00) - globenewswire.com
CWT | News | $44.9 1.65% 0.0% 340K |

Utilities

| -25.27% | O: -0.17% H: 0.48% C: -0.02%
treatment

---

Journal of Medical Economics Article Demonstrates Economic Benefits of Cardiovascular Systems Orbital Atherectomy in the Treatment of Peripheral Artery Disease (PAD)
Published: 2021-05-03 (Crawled : 21:00) - biospace.com/
CSII | News | $20.0 -0.05% 400K |

Health Technology

| -50.4% | O: 0.92% H: 0.0% C: -1.7%
disease treatment cardiovascular cardio

---

Zealand Pharma announces publication of Phase 3 trial evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with diabetes
Published: 2021-05-03 (Crawled : 18:00) - biospace.com/
ZEAL | $17.59 1.21% -4.21% |

Health Technology

| -46.7% | O: 0.55% H: 1.25% C: -0.69%
diabetes treatment hypoglycemia phase 3 trial

---

MoonLake Immunotherapeutics in-licenses potentially best-in-class Tri-specific Nanobody®,[6] Sonelokimab (M1095/ALX 0761) from Merck KGaA, Darmstadt, Germany, with goal of transforming treatment of inflammatory diseases driven by IL-17A and F
Published: 2021-05-03 (Crawled : 15:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -11.95% | O: -4.18% H: 1.62% C: 1.41%
disease treatment potential license germany

---

Medtronic Announces CE Mark of Evolut™ PRO+ TAVI System for Treatment of Symptomatic Severe Aortic Stenosis Patients in Europe
Published: 2021-05-03 (Crawled : 15:00) - biospace.com/
MDT | News | $79.19 0.14% 0.0% 6.1M |

Health Technology

| -39.6% | O: 0.64% H: 0.11% C: -0.43%
treatment europe ce mark

---

Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2021-05-03 (Crawled : 14:00) - biospace.com/
RGLS | $2.22 -5.13% -5.41% 200K |

Health Technology

| 68.35% | O: -2.16% H: 2.18% C: -17.65%
disease treatment phase 1 trial topline phase 1b kidney phase 2b

---

Galmed Announces Approval of IND Application in China for Aramchol for the Treatment of NASH & Fibrosis in the Global Phase 3 ARMOR Registrational Study
Published: 2021-05-03 (Crawled : 14:00) - biospace.com/
GLMD | $0.3669 -0.41% -0.41% 27K |

Health Technology

| -88.65% | O: 1.23% H: 3.55% C: -0.91%
treatment fibrosis china phase 3 nash approval application aramchol

---

Novan Announces Final Week-12 Visit for Last Patient in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
Published: 2021-05-03 (Crawled : 13:15) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M |

Health Technology

| -93.13% | O: 2.19% H: 2.86% C: -8.57%
molluscum treatment phase 3

---

Amicus Therapeutics Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe Disease
Published: 2021-05-03 (Crawled : 12:00) - biospace.com/
FOLD F | $10.35 -1.9% -1.93% 1.7M |

Health Technology

| 7.22% | O: 3.76% H: 2.94% C: 0.69%
disease treatment fda

---

Geisinger becomes first in U.S. to treat cancer patients with Accuray Synchrony® technology on the Radixact® and CyberKnife® S7™ Systems to better target radiation treatments
Published: 2021-05-03 (Crawled : 12:00) - biospace.com/
ARAY | News | $2.21 0.91% 0.9% 690K |

Health Technology

| -52.34% | O: 0.85% H: 0.21% C: -1.69%
treatment cancer technology

---

Gain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson’s Disease & Related α-synucleopathies at the XXVI IAPRD World Congress
Published: 2021-05-03 (Crawled : 12:00) - biospace.com/
GANX | $3.15 -0.94% -0.95% 78K |

Professional, Scientific, and T...

| -73.68% | O: 0.08% H: 0.2% C: -4.71%
disease treatment positive leo parkinson train in vitro

---

Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
Published: 2021-05-03 (Crawled : 12:00) - biospace.com/
ITCI 1 d | $72.01 -6.1% -6.5% 4.7M |

Health Technology

| 126.43% | O: 0.81% H: 0.48% C: 0.09%
treatment fda fda acceptance depression therapy

---

Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis
Published: 2021-05-03 (Crawled : 12:00) - biospace.com/
BHC | $8.6 -0.69% 0.0% 2.1M |

Health Technology

| -72.83% | O: 0.09% H: 0.68% C: -2.42%
CLSD | $1.32 4.76% 4.55% 330K |

Health Technology

| -62.54% | O: 1.63% H: 1.28% C: -4.49%
new drug treatment drug macular submission xipere application resubmission

---

Medical Treatments to Quit Smoking
Published: 2021-05-03 (Crawled : 11:00) - brainsway.com
BWAY | News | $4.8 -4.95% -5.21% 80K |

Health Technology

| -41.3% | O: 0.46% H: 0.35% C: 0.35%
treatment

---

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | $1.02 155.0% 57.94% 120M |

Finance

ZCMD | $2.86 108.76% 52.1% 2.3M |

Commercial Services

INVO | $1.555 104.6% 51.13% 5M |

Health Technology

ISPC | $0.437 105.16% 49.53% 37M |

Professional, Scientific, and T...

WLGS | $0.92 84.0% 45.65% 1.6M |

OST | $0.499 21.38% 45.26% 1.9M |

XPON | $3.1 60.62% 37.74% 17M |

TIRX | $0.7 44.39% 30.74% 58M |

BNTC | $6.92 44.17% 30.64% 3.5M |

Health Technology

GGE | $0.035 19.86% 29.3% 64M |

---

Your saved searches

---